|
1
|
Quinn KE, Mackie DI and Caron KM: Emerging
roles of atypical chemokine receptor 3 (ACKR3) in normal
development and physiology. Cytokine. 109:17–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Britton C, Poznansky MC and Reeves P:
Polyfunctionality of the CXCR4/CXCL12 axis in health and disease:
Implications for therapeutic interventions in cancer and
immune-mediated diseases. FASEB J. 35:e212602021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi Y, Riese DJ II and Shen J: The Role of
the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol.
11:5746672020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luker GD, Yang J, Richmond A, Scala S,
Festuccia C, Schottelius M, Wester HJ and Zimmermann J: At the
Bench: Pre-clinical evidence for multiple functions of CXCR4 in
cancer. J Leukoc Biol. 109:969–989. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu T, Yang W, Sun A, Wei Z and Lin Q: The
Role of CXC chemokines in cancer progression. Cancers (Basel).
15:1672022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Puchert M, Koch C and Engele J: The 5T4
oncofetal glycoprotein does not act as a general organizer of the
CXCL12 system in cancer cells. Exp Cell Res. 364:175–183. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heuninck J, Perpiñá Viciano C, Işbilir A,
Caspar B, Capoferri D, Briddon SJ, Durroux T, Hill SJ, Lohse MJ,
Milligan G, et al: Context-Dependent Signaling of CXC chemokine
receptor 4 and atypical chemokine receptor 3. Mol Pharmacol.
96:778–793. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mo H, Ren Q, Song D, Xu B, Zhou D, Hong X,
Hou FF, Zhou L and Liu Y: CXCR4 induces podocyte injury and
proteinuria by activating β-catenin signaling. Theranostics.
12:767–781. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
D'Agostino G, Artinger M, Locati M, Perez
L, Legler DF, Bianchi ME, Rüegg C, Thelen M, Marchese A, Rocchi
MBL, et al: β-Arrestin1 and β-Arrestin2 Are Required to Support the
Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4. Front Immunol.
11:5508242020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhuo Y, Gurevich VV, Vishnivetskiy SA,
Klug CS and Marchese A: A non-GPCR-binding partner interacts with a
novel surface on β-arrestin1 to mediate GPCR signaling. J Biol
Chem. 295:14111–14124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donà E, Barry JD, Valentin G, Quirin C,
Khmelinskii A, Kunze A, Durdu S, Newton LR, Fernandez-Minan A,
Huber W, et al: Directional tissue migration through a
self-generated chemokine gradient. Nature. 503:285–289. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koch C and Engele J: Functions of the
CXCL12 Receptor ACKR3/CXCR7-What has been perceived and what has
been overlooked. Mol Pharmacol. 98:577–585. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gentilini A, Caligiuri A, Raggi C,
Rombouts K, Pinzani M, Lori G, Correnti M, Invernizzi P, Rovida E,
Navari N, et al: CXCR7 contributes to the aggressive phenotype of
cholangiocarcinoma cells. Biochim Biophys Acta Mol Basis Dis.
18652246–2256. 2029.PubMed/NCBI
|
|
14
|
Xu S, Tang J, Wang C, Liu J, Fu Y and Luo
Y: CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.
Cell Death Dis. 10:1912019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee E, Han J, Kim K, Choi H, Cho EG and
Lee TR: CXCR7 mediates SDF1-induced melanocyte migration. Pigment
Cell Melanoma Res. 26:58–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fumagalli A, Heuninck J, Pizzoccaro A,
Moutin E, Koenen J, Séveno M, Durroux T, Junier MP, Schlecht-Louf
G, Bachelerie F, et al: The atypical chemokine receptor 3 interacts
with Connexin 43 inhibiting astrocytic gap junctional intercellular
communication. Nat Commun. 11:48552020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Odemis V, Lipfert J, Kraft R, Hajek P,
Abraham G, Hattermann K, Mentlein R and Engele J: The presumed
atypical chemokine receptor CXCR7 signals through G(i/o) proteins
in primary rodent astrocytes and human glioma cells. Glia.
60:372–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng Y, Qu J, Che X, Xu L, Song N, Ma Y,
Gong J, Qu X and Liu Y: CXCL12/SDF-1α induces migration via
SRC-mediated CXCR4-EGFR cross-talk in gastric cancer cells. Oncol
Lett. 14:2103–2110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Conley-LaComb MK, Semaan L, Singareddy R,
Li Y, Heath EI, Kim S, Cher ML and Chinni SR: Pharmacological
targeting of CXCL12/CXCR4 signaling in prostate cancer bone
metastasis. Mol Cancer. 15:682016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kasina S, Scherle PA, Hall CL and Macoska
JA: ADAM-mediated amphiregulin shedding and EGFR transactivation.
Cell Prolif. 42:799–812. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chinni SR, Yamamoto H, Dong Z, Sabbota A,
Bonfil RD and Cher ML: CXCL12/CXCR4 transactivates HER2 in lipid
rafts of prostate cancer cells and promotes growth of metastatic
deposits in bone. Mol Cancer Res. 6:446–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cabioglu N, Summy J, Miller C, Parikh NU,
Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE:
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu
in breast cancer cells by a novel pathway involving Src kinase
activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Porcile C, Bajetto A, Barbieri F, Barbero
S, Bonavia R, Biglieri M, Pirani P, Florio T and Schettini G:
Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates
ovarian cancer cell growth through the EGF receptor
transactivation. Exp Cell Res. 308:241–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan
M, Zhou X, Xia W, Hortobagyi GN, Yu D and Hung MC: Upregulation of
CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell.
6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McGinn OJ, Marinov G, Sawan S and Stern
PL: CXCL12 receptor preference, signal transduction, biological
response and the expression of 5T4 oncofoetal glycoprotein. J Cell
Sci. 125:5467–5478. 2012.PubMed/NCBI
|
|
26
|
Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S,
Sakmar TP and Sachdev P: CXCR7/CXCR4 heterodimer constitutively
recruits beta-arrestin to enhance cell migration. J Biol Chem.
286:32188–32197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Del Molino Del Barrio I, Wilkins GC,
Meeson A, Ali S and Kirby JA: Breast Cancer: An examination of the
potential of ACKR3 to modify the response of CXCR4 to CXCL12. Int J
Mol Sci. 19:35922018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, He L, Combs CA, Roderiquez G and
Norcross MA: Dimerization of CXCR4 in living malignant cells:
Control of cell migration by a synthetic peptide that reduces
homologous CXCR4 interactions. Mol Cancer Ther. 5:2474–2483. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martínez-Muñoz L, Rodríguez-Frade JM,
Barroso R, Sorzano CÓS, Torreño-Pina JA, Santiago CA, Manzo C,
Lucas P, García-Cuesta EM, Gutierrez E, et al: Separating
Actin-dependent chemokine receptor nanoclustering from dimerization
indicates a role for clustering in CXCR4 signaling and function.
Mol Cell. 70:106–119.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
DeNies MS, Smrcka AV, Schnell S and Liu
AP: β-arrestin mediates communication between plasma membrane and
intracellular GPCRs to regulate signaling. Commun Biol. 3:7892020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng K, Smith JS, Eiger DS, Warman A,
Choi I, Honeycutt CC, Boldizsar N, Gundry JN, Pack TF, Inoue A, et
al: Biased agonists of the chemokine receptor CXCR3 differentially
signal through Gαi: β-arrestin complexes. Sci Signal.
15:eabg52032022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Santagata S, Ieranò C, Trotta AM,
Capiluongo A, Auletta F, Guardascione G and Scala S: CXCR4 and
CXCR7 signaling pathways: A focus on the cross-Talk between cancer
cells and tumor microenvironment. Front Oncol. 11:5913862021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Raza S, Rajak S, Tewari A, Gupta P,
Chattopadhyay N, Sinha RA and Chakravarti B: Multifaceted role of
chemokines in solid tumors: From biology to therapy. Semin Cancer
Biol. 86:1105–1121. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luker KE, Gupta M and Luker GD: Imaging
chemokine receptor dimerization with firefly luciferase
complementation. FASEB J. 23:823–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Levoye A, Balabanian K, Baleux F,
Bachelerie F and Lagane B: CXCR7 heterodimerizes with CXCR4 and
regulates CXCL12-mediated G protein signaling. Blood.
113:6085–6093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koch C, Fischer NC, Puchert M and Engele
J: Interactions of the chemokines CXCL11 and CXCL12 in human tumor
cells. BMC Cancer. 22:13352022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Uribe ML, Marrocco I and Yarden Y: EGFR in
Cancer: Signaling mechanisms, drugs, and acquired resistance.
Cancers (Basel). 13:27482021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zuccolo E, Di Buduo C, Lodola F,
Orecchioni S, Scarpellino G, Kheder DA, Poletto V, Guerra G,
Bertolini F, Balduini A, et al: Stromal cell-derived factor-1α
promotes endothelial colony-forming cell migration through the
Ca2+-Dependent activation of the extracellular signal-regulated
kinase 1/2 and phosphoinositide 3-kinase/AKT pathways. Stem Cells
Dev. 27:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang Y, Lim J, Wu KC, Xu W, Suen JY and
Fairlie DP: PAR2 induces ovarian cancer cell motility by merging
three signalling pathways to transactivate EGFR. Br J Pharmacol.
178:913–932. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lan L, Wang H, Yang R, Liu F, Bi Q, Wang
S, Wei X, Yan H and Su R: R2-8018 reduces the proliferation and
migration of non-small cell lung cancer cells by disturbing
transactivation between M3R and EGFR. Life Sci. 234:1167422019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hopkins MM, Liu Z and Meier KE: Positive
and negative cross-talk between lysophosphatidic acid receptor 1,
free fatty acid receptor 4, and epidermal growth factor receptor in
human prostate cancer cells. J Pharmacol Exp Ther. 359:124–133.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu J, Liu Y, Ma Y, Wang R, Ji X, Zhang Y
and Du Y: Interaction between CXCR4 and EGFR and downstream
PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted
tumor in nude mice. Int J Clin Exp Pathol. 13:132–141.
2020.PubMed/NCBI
|
|
44
|
Liu B, Song S, Setroikromo R, Chen S, Hu
W, Chen D, van der Wekken AJ, Melgert BN, Timens W, van den Berg A,
et al: CX Chemokine Receptor 7 contributes to survival of
KRAS-Mutant Non-Small cell lung cancer upon loss of epidermal
growth factor receptor. Cancers (Basel). 11:4552019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zuo J, Wen M, Li S, Lv X, Wang L, Ai X and
Lei M: Overexpression of CXCR4 promotes invasion and migration of
non-small cell lung cancer via EGFR and MMP-9. Oncol Lett.
14:7513–7521. 2017.PubMed/NCBI
|
|
46
|
Lopez-Haber C, Barrio-Real L,
Casado-Medrano V and Kazanietz MG: Heregulin/ErbB3 signaling
enhances CXCR4-driven Rac1 activation and breast cancer cell
motility via hypoxia-inducible factor 1α. Mol Cell Biol.
36:2011–2026. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC,
Yang PC and Shih JY: EGFR-L858R mutant enhances lung adenocarcinoma
cell invasive ability and promotes malignant pleural effusion
formation through activation of the CXCL12-CXCR4 pathway. Sci Rep.
5:135742015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Boudot A, Kerdivel G, Lecomte S, Flouriot
G, Desille M, Godey F, Leveque J, Tas P, Le Dréan Y and Pakdel F:
COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF
signaling and stimulates breast cancer cell migration. BMC Cancer.
14:4072014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo
ZY, Zhao J, Meng YL, Ren XL, Wang T, et al: HER2 interacts with
CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139
in gastric cancer cells. Gastroenterology. 141:2076–2087.e6. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yasumoto K, Yamada T, Kawashima A, Wang W,
Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K and
Yano S: The EGFR ligands amphiregulin and heparin-binding egf-like
growth factor promote peritoneal carcinomatosis in CXCR4-expressing
gastric cancer. Clin Cancer Res. 17:3619–3630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rahimi M, George J and Tang C: EGFR
variant-mediated invasion by enhanced CXCR4 expression through
transcriptional and post-translational mechanisms. Int J Cancer.
126:1850–1860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y,
Ma W, Hu H, Cai S and Liu Y: The synergistic effects of CXCR4 and
EGFR on promoting EGF-mediated metastasis in ovarian cancer cells.
Colloids Surf B Biointerfaces. 60:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kallifatidis G, Munoz D, Singh RK, Salazar
N, Hoy JJ and Lokeshwar BL: β-Arrestin-2 counters CXCR7-mediated
EGFR transactivation and proliferation. Mol Cancer Res. 14:493–503.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Salazar N, Muñoz D, Kallifatidis G, Singh
RK, Jordà M and Lokeshwar BL: The chemokine receptor CXCR7
interacts with EGFR to promote breast cancer cell proliferation.
Mol Cancer. 13:1982014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Singh RK and Lokeshwar BL: The
IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling
to promote prostate cancer growth. Cancer Res. 71:3268–3277. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Abourehab MAS, Alqahtani AM, Youssif BGM
and Gouda AM: Globally approved EGFR inhibitors: Insights into
their syntheses, target kinases, biological activities, receptor
interactions, and metabolism. Molecules. 26:66772021. View Article : Google Scholar : PubMed/NCBI
|
